A new white paper by the Pharmacy Benefit Management Institute (PBMI) outlines ways that some drug manufacturers undermine formulary and utilization management tools, resulting in higher drug costs for health plan sponsors and patients. Read Report
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) supports the Centers for Medicare and Medicaid Services’ (CMS) proposal to promote the use of biosimilars in Medicare Part D. Pharmacy benefit companies, or PBMs, have long supported the development of
The news this week that the Food and Drug Administration (FDA) approved Aduhelm to treat Alzheimer’s disease has been met with hope, but also skepticism in terms of the drug’s clinical safety and efficacy, and its cost.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the House Energy and Commerce Health Subcommittee’s consideration of H.R. 3528 / S. 2460 the Every Prescription Conveyed Securely Act, which requires electronic prescribing (e-prescribing) for
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s vote in the Energy and Commerce Subcommittee on Health on the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act:
The PCMA Business Forum 2024 took place at the Signia by Hilton Orlando, Bonnet Creek in Orlando, FL, on March 11 & 12. Don’t miss the industry’s most important business development, networking and educational conference. The Business Forum is a
A new paper from University of Chicago economics professor Casey Mulligan, The Value of Pharmacy Benefit Management, finds that pharmacy benefit managers (PBMs) create $145 billion in value every year.
In a new web video, Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott discusses the critical role and value of pharmacy benefit companies, the root cause of high prescription drug prices, and how solutions to boost competition, especially
As our nation works tirelessly to address the coronavirus (COVID-19), on behalf of the pharmacy benefit management (PBM) industry, the Pharmaceutical Care Management Association (PCMA) affirms our commitment to support federal, state, and local public health agencies; collaborate with health
A new research paper from Matrix Global Advisors, Improvements in Medical Benefit Coverage of Biosimilars, finds that commercial medical benefit insurance coverage of biosimilars has been increasing since 2019 as the prices of these biosimilars have been declining in three
©2024 PCMA. All Rights Reserved.
